Mapping Epileptic Networks with MRI and iEEG
Optimized Intracranial EEG Targeting in Focal Epilepsy Based Upon Neuroimaging Connectomics
This study is testing a new way to use MRI and brain wave recordings to help people with hard-to-treat epilepsy understand their seizures better and improve their chances of successful surgery.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 290 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT04649008 on ClinicalTrials.gov |
What this trial studies
This study aims to develop noninvasive imaging biomarkers that can predict the functional dynamics of intracranial EEG (iEEG) and surgical outcomes for patients with intractable epilepsy. By integrating MRI and iEEG data, the researchers seek to create tools that can accurately map epileptic networks, potentially reducing the need for invasive diagnostic procedures. The study focuses on patients with temporal lobe epilepsy who are scheduled for iEEG placement, and it will explore the relationship between structural and functional brain measures and seizure dynamics. The ultimate goal is to enhance patient-specific interventions and improve surgical outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with medication-refractory epilepsy who are planned for intracranial EEG placement and are hypothesized to have temporal lobe epilepsy.
Not a fit: Patients with contraindications to MRI, prior intracranial surgery, or non-diagnostic iEEG findings may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to less invasive and more effective treatments for patients with drug-resistant epilepsy.
How similar studies have performed: Other studies have shown promise in using noninvasive imaging techniques to improve epilepsy treatment, but this specific approach is innovative and aims to validate new biomarkers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with medication-refractory epilepsy * Planned intracranial EEG (IEEG) placement * Hypothesized to have temporal lobe epilepsy Exclusion Criteria: * Contraindication to 3T MRI (e.g. metal implants or claustrophobia), clinical features that typically preclude the use of IEEG (e.g. pregnancy), prior intracranial surgery or device, and IEEG findings that are non-diagnostic (e.g. seizure onset zone(s) not identified)
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Kathryn A Davis, MD, MSTR — University of Pennsylvania
- Study coordinator: Kathryn A Davis, MD, MSTR
- Email: katedavis@pennmedicine.upenn.edu
- Phone: 215-349-5166
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.